Supplements
Download PDF
David J. Straus, MD
Christine Liebertz, RN, CS, MSN, AOCN
Nelly G. Adel, PharmD, BCOP, BCPS

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: April 21st, 2011 - April 21st, 2012

Target Audience
The educational design of this activity addresses the needs of physicians, nurses, and pharmacists involved in the treatment of patients with Hodgkin lymphoma (HL).
 

Statement of Need
The purpose of this activity is to enhance knowledge concerning the treatment of patients with HL.


Educational Objectives
After completing this activity, the participant should be better able to:

  • Review current management strategies and expected outcomes for newly diagnosed and relapsed/refractory HL
  • Summarize results from recent clinical trials evaluating the safety and efficacy of newer therapies for HL, in both the frontline and salvage settings
  • Compare the risks and benefits of radiation therapy in the treatment of patients with HL
  • Assess effective strategies for preventing and/or minimizing common toxicities associated with newer therapies for HL

Agenda - 1.5 hours
• Articles/Commentaries: 75 minutes
• Evaluation/Post-Test: 15 minutes


Physician Continuing Education Accreditation
This activity has been planned and implemented in accordance with the  Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Global Education Group (Global) and Medical Learning Institute, Inc. (MLI). Global is accredited by the ACCME to provide continuing medical education for physicians.


Physician Credit Designation
Global designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:


Faculty Disclosures
*Nelly G. Adel, PharmD, BCOP, BCPS, has nothing to disclose.




*Stephanie A. Gregory, MD  is on advisory boards for Amgen, Genentech, and Novartis. She has received research support from Astellas, Celgene, Cephalon, Genentech, GlaxoSmithKline, Immunomedics, NCIC CTG, Novartis, and Onyx.

Christine Liebertz, RN, CS, MSN, AOCN, has nothing to disclose.

*David J. Straus, MD is on advisory boards for Centocor Ortho Biotech, Inc., and has received research support from Centocor Ortho Biotech, Inc., and Merck.

*Content will include non-FDA-approved uses.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:



Name of Planner
or Manager
Company Reported Financial
Relationship
Dana Delibovi COEXM Nothing to disclose
Jackie Dawson, MSN Global Nothing to disclose
Amanda Glazar, PhD Global Nothing to disclose
Shelley Chun, PharmD MLI Nothing to disclose
Kathryn Gada, MSN MLI Nothing to disclose


Disclaimer
The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Related Items
Considerations in Non-Hodgkin's Lymphoma: Clinical Trial Updates
André Goy, MD, MS, Amanda Copeland, MSN, RN, CNS, Anas Younes, MD, Sandra E. Kurtin, RN, MS, AOCN, ANP-C, Nelly G. Adel, PharmD, BCOP, BCPS
Supplements published on February 2, 2010
Considerations in Non-Hodgkin's Lymphoma: Diffuse Large B-Cell Lymphoma
André Goy, MD, MS, Betty M. Chan, PharmD, BCOP, Christine Liebertz, RN, CS, MSN, AOCN
Supplements published on November 6, 2009
Last modified: March 21, 2014